After decades under Johnson & Johnson, a massive plant that once cranked out over-the-counter mainstays like Pepcid and Imodium is poised to hit the market. The plant handover comes after last month’s news that Johnson & Johnson would cut 57 positions at the Lancaster County facility, as detailed in a local Worker Adjustment and Retraining Notification Act notice. High Properties acquired J&J’s Greenfield, Pennsylvania, consumer health facility for $14 million, local news outlet Lancaster Online first reported. Fierce Pharma has viewed a copy of the deed confirming the sale, which went through in late March. J&J and High Properties did not immediately respond to Fierce Pharma’s request for comment on the matter. Reference: https://deal.town/questex/041223-takeda-hit-with-another-pay-for-delay-lawsuit-after-layoff-warning-jandj-inks-14m-plant-sale-F34YGQUSL
In an effort to know more about the etiopathogenesis of non-treatment responding to depression and to improve its management, Takeda and ConvergeHEALTH, data science institute by Deloitte collaborate to analyze patient datastores.
The Newton Massachusetts-based company, Karyopharm Therapeutics, who developed a new class of drugs to treat multiple myeloma, is in the process of submitting a new drug application to the FDA for their selinexor drug.
Recent news regarding pharma companies in Asia
The DDF initially aimed to raise £130 million with committed investments from GlaxoSmithKline, Biogen, Eli Lilly, Pfizer and Takeda, Johnson & Johnson, as well as the U.K. government’s Department of Health and the nonprofit Alzheimer’s Research UK.
When the FDA approved this drug, there was an additional demand from the FDA to conduct post-marketing studies and assess the drug’s safety. Recently, a non-profit consumer advocacy group sent a petition requesting that the FDA should eliminate the drug from the U.S. pharma market since the drug shows significant risk of cardiovascular diseases.
This is the second partnership of the firm, the first outside oncology. It has a USD 790 million collaboration signed in 2016 with drugmaker Takeda of Japan. The deal with Zai Lab is the first for Crescendo to involve a specific pipeline asset. The deal with Takeda was more of a platform agreement giving it the required confidence to collaborate with other programs in oncology.
EHR vendor Allscripts has made an agreement to purchase patient communication app maker Health Grid for $60 million in cash, with an additional $50 million in earnout payments based on Health Grid achieving certain revenue targets over the next three years, according to a recently registered SEC filing. The merger of the two companies is expected to close sometime during Q2 2018.
Sale of Oncology business unlocks embedded value within Shire`s portfolio and sharpens focus on core areas reinforcing our leadership in rare diseases
Denali Therapeutics Inc. (NASDAQ:DNLI), a biopharmaceutical company developing a broad portfolio of therapeutic candidates for neurodegenerative diseases, today announced that it has commenced dosing of its small molecule inhibitor of RIPK1 in a Phase 1 clinical trial in healthy volunteers and achieved proof of concept of its large molecule blood-brain barrier delivery platform technology in nonhuman primates.
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.